WallStSmart
RNAC

Cartesian Therapeutics Inc.

NASDAQ: RNAC · HEALTHCARE · BIOTECHNOLOGY

$6.22
-3.86% today

Updated 2026-04-30

Market cap
$199.26M
P/E ratio
P/S ratio
71.24x
EPS (TTM)
$-5.02
Dividend yield
52W range
$6 – $16
Volume
0.2M

Cartesian Therapeutics Inc. (RNAC) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
-59.8%
Last 4 quarters
Revenue YoY growth
-224.8%
Most recent quarter
EPS YoY growth
-356.0%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+13.7%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+24.8%
2026-03-09
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-09$-2.71-242.6%$6.85$8.55+24.8%
2025-11-06$-1.38-53.3%$7.67$7.87+2.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.79$-2.71-242.6%$947000.00-224.8%
2025-09-30$-0.90$-1.38-53.3%$452000.00+16.8%
2025-06-30$-0.82$-0.77+5.8%$298000.00-99.1%
2025-03-31$-0.71$-0.65+8.5%$1.10M-81.2%
2024-12-31$-0.83$-0.59+28.1%$-759000.00-109.2%
2024-09-30$-0.55$-0.42+23.6%$387000.00-94.1%
2024-06-30$-0.09$0.64+811.1%$33.45M+537.2%
2024-03-31$-1.42$-0.80+43.7%$5.84M-1.7%
2023-12-31$-0.04$-0.07-75.0%$8.27M
2023-09-30$-0.06$-0.06+0.0%$6.55M
2023-06-30$-0.08$-0.07+12.5%$5.25M
2023-03-31$-0.09$-0.14-55.6%$5.94M

Frequently asked questions

Has Cartesian Therapeutics Inc. beaten earnings estimates?
Cartesian Therapeutics Inc. has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of -59.8% over the last 4 quarters.
How does RNAC stock react to earnings?
RNAC stock has moved an average of +13.7% in the trading day following earnings over its last 2 reports, with positive reactions in 100% of those quarters.
What is Cartesian Therapeutics Inc.'s revenue growth rate?
Cartesian Therapeutics Inc. reported year-over-year revenue growth of -224.8% in its most recent quarter, with EPS growing -356.0% year-over-year.